Siglec-15 Silencing Inhibits Cell Proliferation and Promotes Cell Apoptosis by Inhibiting STAT1/STAT3 Signaling in Anaplastic Thyroid Carcinoma
文献类型：期刊论文
| 作者 | Hou, Xiaofeng1,2,3; Chen, Chao1,3; He, Xiaodong2; Lan, Xiabin1,3 |
| 刊名 | DISEASE MARKERS
 |
| 出版日期 | 2022-06-20 |
| 卷号 | 2022 |
| ISSN号 | 0278-0240 |
| DOI | 10.1155/2022/1606404 |
| 通讯作者 | He, Xiaodong(houxf18@lzu.edu.cn) ; Lan, Xiabin(lanxb99@126.com) |
| 英文摘要 | Thyroid cancer (THCA) represents a frequently seen endocrine cancer, which can be divided as anaplastic thyroid carcinoma (ATC), follicular thyroid carcinoma (FTC), and papillary thyroid carcinoma (PTC). A total of 362 IDEGs were obtained from TCGA-THCA and IMMPORT databases, which were found to be related to BP, CC, MF, and STAT signaling pathway upon GO functional annotation and KEGG analysis. This work identified 23 survival-related hub genes using WGCNA and uniCOX analysis. In addition, a risk prognosis model was constructed to obtain a signature involving fifteen IDEGs. According to survival and univariate along with multivariate analysis, high-risk patients had markedly dismal prognostic outcome compared with low-risk counterparts. Siglec-15 belongs to one of the fifteen IDEG signature, but the precise biological roles in diverse THCA subtypes are largely unclear. In this work, Siglec-15 expression evidently increased in ATC and FTC samples compared with matched surrounding PTC and THCA samples, which was used as a diagnostic biomarker for THCA. Siglec-15 RNAi significantly inhibited cell proliferation and promoted cell apoptosis. Meanwhile, Siglec-15 knockout suppressed the expression of STAT1, STAT3, and VEGF and promoted that of cleaved caspase-3. In vivo experiments revealed that transfection with vectors expressing STAT1 and STAT3 inhibited the Siglec-15 RNAi-induced inhibition on tumor growth and the increases in CD4(+)/CD8(+) ratio. In conclusion, Siglec-15 expression increases in ATC and FTC, which promotes THCA occurrence via the STAT1/STAT3 signaling, in particular for FTC and ATC. Therefore, it is the possible marker that can be used to diagnose and treat THCA. |
| WOS关键词 | CANCER ; IMMUNOTHERAPY |
| WOS研究方向 | Biotechnology & Applied Microbiology ; Genetics & Heredity ; Research & Experimental Medicine ; Pathology |
| 语种 | 英语 |
| 出版者 | HINDAWI LTD |
| WOS记录号 | WOS:000852889200001 |
| 源URL | [http://ir.hfcas.ac.cn:8080/handle/334002/131682]  |
| 专题 | 中国科学院合肥物质科学研究院 |
| 通讯作者 | He, Xiaodong; Lan, Xiabin |
| 作者单位 | 1.Chinese Acad Sci, Univ Chinese Acad Sci, Zhejiang Canc Hosp,Dept Head & Neck Oncol Surg, Inst Basic Med & Canc IBMC,Canc Hosp, Hangzhou 310022, Zhejiang, Peoples R China 2.Lanzhou Univ, Clin Med Coll 2, Dept Gen Surg, Lanzhou 730030, Gansu, Peoples R China 3.Key Lab Head & Neck Canc Translat Res Zhejiang Pr, Hangzhou 310022, Zhejiang, Peoples R China |
| 推荐引用方式 GB/T 7714 | Hou, Xiaofeng,Chen, Chao,He, Xiaodong,et al. Siglec-15 Silencing Inhibits Cell Proliferation and Promotes Cell Apoptosis by Inhibiting STAT1/STAT3 Signaling in Anaplastic Thyroid Carcinoma[J]. DISEASE MARKERS,2022,2022. |
| APA | Hou, Xiaofeng,Chen, Chao,He, Xiaodong,&Lan, Xiabin.(2022).Siglec-15 Silencing Inhibits Cell Proliferation and Promotes Cell Apoptosis by Inhibiting STAT1/STAT3 Signaling in Anaplastic Thyroid Carcinoma.DISEASE MARKERS,2022. |
| MLA | Hou, Xiaofeng,et al."Siglec-15 Silencing Inhibits Cell Proliferation and Promotes Cell Apoptosis by Inhibiting STAT1/STAT3 Signaling in Anaplastic Thyroid Carcinoma".DISEASE MARKERS 2022(2022). |
入库方式： OAI收割
来源：合肥物质科学研究院
浏览0
下载0
收藏0
其他版本
除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。